The multi-dose, single-patient-use, prefilled pen allows for personalized treatment plans that can cater to individual patient needs "The availability of all doses of Mounjaro KwikPen represents a ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Ohio Attorney General Dave Yost sent letters to 14 medical spas warning them to stop making false or misleading claims about ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

Although shortages of brand-name tirzepatide injections have occurred, the FDA declared the shortage resolved in 2024. At that time, the FDA announced that compounding pharmacies could no longer ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.

Availability of GLP-1 receptor agonists with managed care organization (MCO) plans has remained under 60% since 2020. Access to tirzepatide (Mounjaro, Zepbound) was nearly completely restricted ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

This comprehensive review explores MEDVi, a leading telehealth provider offering compounded GLP-1 weight loss solutions like Semaglutide and Tirzepatide in both injection and tablet form.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...